Insider Selling: ClearPoint Neuro (NASDAQ:CLPT) Director Sells $56,713.74 in Stock

ClearPoint Neuro, Inc. (NASDAQ:CLPT) Director Lynnette Fallon sold 5,091 shares of the company’s stock in a transaction dated Wednesday, May 20th. The stock was sold at an average price of $11.14, for a total value of $56,713.74. Following the completion of the transaction, the director directly owned 48,227 shares in the company, valued at approximately $537,248.78. The trade was a 9.55% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

ClearPoint Neuro Stock Performance

Shares of CLPT stock opened at $11.44 on Friday. The company has a debt-to-equity ratio of 2.63, a current ratio of 5.79 and a quick ratio of 4.88. ClearPoint Neuro, Inc. has a fifty-two week low of $8.27 and a fifty-two week high of $30.10. The stock’s 50-day moving average is $10.55 and its two-hundred day moving average is $12.79. The firm has a market cap of $343.09 million, a P/E ratio of -11.33 and a beta of 1.29.

ClearPoint Neuro (NASDAQ:CLPT) last released its quarterly earnings results on Wednesday, May 13th. The company reported ($0.32) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.28) by ($0.04). The company had revenue of $12.13 million for the quarter, compared to the consensus estimate of $11.97 million. ClearPoint Neuro had a negative return on equity of 140.96% and a negative net margin of 71.57%. Analysts predict that ClearPoint Neuro, Inc. will post -1.05 earnings per share for the current fiscal year.

Institutional Trading of ClearPoint Neuro

Several hedge funds have recently added to or reduced their stakes in the business. Bank of America Corp DE boosted its stake in ClearPoint Neuro by 37.4% during the 1st quarter. Bank of America Corp DE now owns 66,075 shares of the company’s stock valued at $601,000 after purchasing an additional 17,990 shares during the period. Quantinno Capital Management LP boosted its stake in ClearPoint Neuro by 307.4% during the 1st quarter. Quantinno Capital Management LP now owns 51,947 shares of the company’s stock valued at $473,000 after purchasing an additional 39,195 shares during the period. Bank of New York Mellon Corp boosted its stake in ClearPoint Neuro by 39.6% during the 1st quarter. Bank of New York Mellon Corp now owns 143,747 shares of the company’s stock valued at $1,308,000 after purchasing an additional 40,741 shares during the period. Hsbc Holdings PLC bought a new stake in ClearPoint Neuro during the 1st quarter valued at approximately $129,000. Finally, SG Americas Securities LLC bought a new stake in ClearPoint Neuro during the 1st quarter valued at approximately $3,388,000. Institutional investors own 30.08% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts have recently issued reports on CLPT shares. Stifel Nicolaus started coverage on ClearPoint Neuro in a research note on Friday, May 8th. They set a “buy” rating and a $16.00 price target for the company. B. Riley Financial upped their price target on ClearPoint Neuro from $18.00 to $20.00 and gave the stock a “buy” rating in a research note on Wednesday, March 18th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of ClearPoint Neuro in a research note on Monday, April 20th. Two investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, ClearPoint Neuro has an average rating of “Hold” and a consensus price target of $18.00.

About ClearPoint Neuro

ClearPoint Neuro, Inc is a medical technology company specializing in the development and commercialization of an MRI-guided therapy platform for minimally invasive neurosurgical procedures. Headquartered in Cambridge, Massachusetts, the company’s flagship ClearPoint® SmartFrame™ system enables surgeons to perform accurate and efficient intracranial interventions by providing real-time magnetic resonance imaging feedback. This technology is designed to improve patient safety and outcomes in treatments ranging from deep brain stimulation electrode placement to laser ablation of epileptic foci and brain tumors.

The ClearPoint System integrates hardware, software and imaging capabilities to guide instruments through the brain with submillimeter precision.